Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119648) titled 'A single-center, randomized, double-blind, placebo-controlled phase I study to evaluate the safety, tolerability and pharmacokinetics of HL-300 ointment after single and multiple administration in healthy adult volunteers' on March 2.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Third Xiangya Hospital Central South University
Condition:
Atopic dermatitis
Intervention:
Group 1:Single transdermal administration of 0.25% HL-300 or placebo (3 cases in the investigational drug group and 1 case in the placebo group)
Group 4:Repeated transdermal administration of 1.0% HL-300 or p...